Invivoscribe Launched LymphoTrack Flex Suite
The San Diego-based firm released a new sequencing solution to support clonality assessment in oncology research.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe advanced molecular testing technology will lead to better overall healthcare outcomes?
Invivoscribe has launched its LymphoTrack Flex suite, a next-generation sequencing solution designed to identify immunoglobulin and T-cell receptor gene rearrangements. The suite is intended to provide laboratories with a standardized, high-throughput workflow for oncology research.
Why it matters
As demand for standardized, high-throughput oncology workflows accelerates, laboratories require increased efficiency and reproducible testing. This suite aims to address those needs by facilitating ultra-high sensitivity and scalability in clonality assessment.
The suite integrates seven molecular targets including IGHV leader and TRG markers to provide comprehensive sequence analysis. Invivoscribe brings this to market after more than thirty years of company operations.
The players
Invivoscribe
A San Diego-based molecular diagnostics company that has operated for more than three decades with laboratory networks in the United States, Germany, Japan, and China.
The details
The LymphoTrack Flex suite utilizes massively parallel multiplexing and a bioinformatics engine to perform analysis. Users can opt for local desktop-based analysis via the standard software or implement the LymphoTrack Enterprise Software for centralized, high-throughput environments.
Timeline
Invivoscribe announced the launch of the LymphoTrack Flex suite on October 6, 2026.
Health Landscape
This launch follows the industry trend toward standardized next-generation sequencing (NGS) clonality assessment workflows to improve research reproducibility. It marks a push to consolidate analysis environments for clinical laboratories facing increasing data demands.
By providing laboratories with highly reproducible and sensitive testing, this technology supports more accurate research and development for cancer treatments. These improvements may eventually lead to more efficient diagnostic processes for patients undergoing oncology care.
The takeaway
The move toward centralized, enterprise-level software underscores the critical role of bioinformatics in modern clinical testing. Laboratories aiming to scale their research should prioritize platforms that offer both local flexibility and high-throughput integration capabilities.
Further reading
For more information on the evolving field of oncology diagnostics, visit the Cancer section.
Source note: This article includes information reported by The Kingston Whig-Standard.
Live Poll
Do you believe advanced molecular testing technology will lead to better overall healthcare outcomes?
